33rd week of 2009 patent applcation highlights part 32 |
Patent application number | Title | Published |
20090202421 | SYNTHETIC DIAMONDS PREPARED FROM ROSES - The present invention relates to a method of making a more permanent remembrance from a gift that includes organic material, wherein the gift has ephemeral beauty and symbolizes the feelings of a gift-giver toward a recipient. This method includes transforming the ephemeral beauty of the gift to a more permanent or eternal manifestation that symbolizes the feelings of the gift-giver toward the recipient. This result is conveniently achieved by initially converting the gift into carbon or a carbon-containing compound that is suitable for preparing a synthetic diamond, and then converting the carbon or carbon-containing compound under suitable pressure and temperature conditions to form a gem quality synthetic diamond. | 2009-08-13 |
20090202422 | METHOD FOR TREATING CARBON NANOTUBES, CARBON NANOTUBES AND CARBON NANOTUBE DEVICE - A method for treating carbon nanotubes is proved, which comprises treating the carbon nanotubes with an aqueous solution containing hydroxyl radicals (HO.). | 2009-08-13 |
20090202423 | Atomic carbon material and method for preparation thereof - An atomic carbon material and a preparation method thereof having ion adsorption ability superior to fullerenes and nano-tubes are provided. This atomic carbon material is in a state existing as an organic compound and in a state close to an atom with a diameter of 1 nm or less (theoretically about 1.66 angstrom), and is a bulk where they are congregated with each other with an interatomic force or a particle with a particle size of 1 nm or less. This atomic carbon material is manufactured by heating a raw material composed of an organic material which does not include carbon units in an inactive atmosphere at a predetermined temperature while sequentially increasing the temperature and by individually separating expected elements except for carbon in the aforementioned atmosphere and the organic material from being bonded with carbon by thermally decomposing in order from an element having a lower decomposition temperature at a temperature of 450 C or lower. | 2009-08-13 |
20090202424 | Calcium-sodium ploysulfide chemical reagent and production methods - A calcium-sodium polysulfide chemical reagent and methods for producing the reagent. The reagent is a blend of calcium polysulfide and sodium polysulfide that can be prepared using various types, sources and ratios of lime, elemental sulfur and sulfide ion using either virgin or waste materials. The reagent is amenable to inexpensive and high rate production methods at ambient or warmer temperatures. The reagent can be used to precipitate metals from wastewater, stabilize hexavalent chrome in hazardous waste residues, remove mercury from coal fired power plants, and as an electrolyte in large-scale bromide/polysulfide electrical storage batteries | 2009-08-13 |
20090202425 | Process for Preparing Barium Titanate - The present invention relates to a hydrothermal synthesis for preparing barium titanate powder as the essential material for a multi-layer ceramic capacitor. The object of the invention is to prepare barium titanate powder having high purity, particle size of submicron order, uniform particle distribution and excellent crys tallinity , by reacting hydrous titanic acid compound prepared via sulfuric acid process with crystalline titanium oxide and barium hydroxide, as the starting material, at a temperature between 60° C. and 300° C. under a pressure between 5 Kgf/cm2 and 50 Kgf/cm2. The process for preparing barium titanate according to the present invention provides barium titanate powder having Ba/Ti molar ratio of 1.000±0.002 and high purity by applying calcination under reductive condition to the solid product obtained from hydrous titanic acid compound prepared via sulfuric acid process with crystalline titanium oxide and barium hydroxide, as the starting substances, to convert barium sulfate, which was produced from residual sulfide in the raw material, to barium titanate. | 2009-08-13 |
20090202426 | Method for producing dielectric powder - Method for producing dielectric powder comprising steps of;
| 2009-08-13 |
20090202427 | PROCESS FOR PREPARING MIXED METAL OXIDE POWDERS - Process for preparing mixed metal oxide powders Abstract Process for preparing a mixed metal oxide powder, in which oxidizable starting materials are evaporated in an evaporation zone of a reactor and oxidized in the vaporous state in an oxidation zone of this reactor, the reaction mixture is cooled after the reaction and the pulverulent solids are removed from gaseous substances, wherein at least one pulverulent metal, together with one or more combustion gases, is fed to the evaporation zone, the metal is evaporated completely in the evaporation zone under nonoxidizing conditions, an oxygen-containing gas and at least one metal compound are fed, separately or together, in the oxidation zone to the mixture flowing out of the evaporation zone, the oxygen content of the oxygen-containing gas being at least sufficient to oxidize the metal, the metal compound and the combustion gas completely. | 2009-08-13 |
20090202428 | Use of Dtbz for Imaging Endocrine Pancreas and Beta Cell Mass In Type 1 Diabetes - The present invention provides non-invasive methods for determining the beta cell mass in the pancreas of a subject by administering to the subject an effective amount of a vesicular monoamine transporter type 2 (VMAT2)-specific radioligand; obtaining at least one computerized image of at least a portion of the pancreas of the subject; and quantitatively analyzing the computerized image in order to determine the beta cell mass in the pancreas of the subject. The present invention additionally provides methods for diagnosing a metabolic neuroendocrine disorder in a subject including insulinoma, diabetes and preclinical diabetes, as well as methods for determining the efficacy of treatment for a metabolic disorder. The present invention further provides methods for assessing the prognosis of a subject at risk for developing diabetes, and methods for managing the treatment or prevention of diabetes. The present invention also provides kits for use in determining the beta cell mass in the pancreas of a subject, as well as diagnosing metabolic or neuroendocrine disorders in a subject. | 2009-08-13 |
20090202429 | METHODS FOR TESTING ANTI-THROMBOTIC AGENTS - The invention provides a transgenic non-human animal expressing von Willebrand Factor A1 protein containing at least one mutation selected from the group consisting of: 1263P>S, 1269N>D, 1274K>R, 1287M>R, 1302G>D, 1308H>R, 1313R>W, 1314I>V, 1326R>H, 1329L>I, 1330E>G, 1333A>D, 1344T>A, 1347I>V, 1350T>A, 1370G>S, 1379H>R, 1381T>A, 1385T>M 1391P>Q, 1394A>S, 1397L>F, 1421S>N, 1439L>V, 1442G>S, 1449R>Q, 1466A>P, 1469Q>L, 1472Q>H, 1473V>M, 1475H>Q, 1479S>G, and any combination thereof. | 2009-08-13 |
20090202430 | COMPOSITION FOR CYTOCOMPATIBLE, INJECTABLE, SELF-GELLING POLYSACCHARIDE SOLUTIONS FOR ENCAPSULATING AND DELIVERING LIVE CELLS OR BIOLOGICALLY ACTIVE FACTORS - The present invention provides compositions and methods for tissue repair using a cytocompatible self-gelling cross-linked hydrogel. The composition comprises a biocompatible mixture of chitosan, bifunctional dialdehyde, and hydroxylated polymer, which can be used to immobilize or encapsulate viable cells, or bioactive substances. The method includes the process of mixing bioactive substances, live cells, and/or extracellular matrix components with a cross-linking solution comprising a bifunctional aldehyde-treated hydroxylated polymer such as hydroxyethyl cellulose. The cross-linking solution is then mixed homogenously with a neutral isotonic chitosan solution. The chitosan becomes cross-linked by the bifunctional aldehyde, while the cells are protected from potentially nocive effects of the aldehyde cross-linker by the hydroxylated polymer. The injectable solution retains cell viability and bioactivity, and immobilizes cells at the site of injection or delivery. Depending on the particular application, mixtures of chitosan and bifunctional dialdehyde may be employed. The injectable solution also liberates bioactive substances with controlled release kinetics from the site of injection. | 2009-08-13 |
20090202431 | STEM-LIKE CELLS IN BONE SARCOMAS - Isolation and purification of stem cells from within a bulk sarcoma tumor. These cells express the marker genes of pluripotent embryonic stem cells, Stat 3, Oct 3/4, and Nanog. A subset of these cells show the surface marker of mesenchymal stem cells Stro-1, as well as express attributes of mesodermal, ectodermal, and endodermal differentiation. The isolation, purification and characterization of these stem cells now provides the ideal target for the development of highly effective therapies against tumors. | 2009-08-13 |
20090202432 | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS - Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease. | 2009-08-13 |
20090202433 | Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses - The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition. | 2009-08-13 |
20090202434 | Pharmaceutical Composition and Dressing for Treating Skin Lesion, as Well as the Use of Cerium Salt Associated With a Collagen Matrix - The present invention refers to a pharmaceutical composition for treating skin lesion, comprising a cerium salt on a collagen matrix and a dermatologically acceptable carrier. The present invention also refers to a wound dressing for treating skin lesion, comprising the pharmaceutical composition of the present invention. The present invention further refers to the use of a cerium salt associated with collagen in the preparation of the pharmaceutical composition or wound dressing according to the present invention. The composition of the present invention can be used in topical applications in a variety of lesion types, such as skin lesions involving the release of toxins related to microbial proteins on human or animal organisms, or those appointed as HSP; burns which involve burned skin toxin formation or LPC; chronically ulcerate skin lesions in which there is an overproduction of proteinase; skin lesions of difficult resolution, in which control of exudate overproduction is required; and critically infected or colonized skin lesions. | 2009-08-13 |
20090202435 | Diagnostic compounds for targeting a chemokine receptors - The present invention relates to a compound comprising, firstly a component for targeting at least one chemokine receptor and, secondly, a detection component capable of being identified by a medical imaging method. | 2009-08-13 |
20090202436 | Bupivacaine Formulation in a Polyorthoester Carrier - Effective treatments of pain, such as chronic pelvic pain, for extended periods of time are provided. The treatments include the administration of one or more drug depots intraspinally wherein the drug depots include an effective amount of bupivacaine formulated within a polyorthoester. By administration of one or more drug depots, one can relieve pain caused by diverse sources, including but not limited to chronic pelvic pain syndromes, spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least thirty days, at least sixty days, at least one hundred days or at least one hundred and thirty-five days. | 2009-08-13 |
20090202437 | Therapeutic Use of Lpi, a Staphylococcal Lectin Pathway Inhibitor in Inflammatory diseases - The invention relates to nucleic acid molecules encoding (poly)peptides having LPI (Lectin Pathway Inhibitor) activity, to recombinant vectors harboring such molecules, and the host cells carrying the vectors. The invention further relates to methods for preparing recombinant (poly)peptides having LPI activity and to the use of such recombinant (poly)peptides having LPI activity for diagnosis, prophylaxis and treatment, such as the treatment of inflammation reactions. In addition the invention provides therapeutic and diagnostic compositions comprising as the active ingredient the (poly)peptide having LPI activity. | 2009-08-13 |
20090202438 | EPITOPE REGIONS OF A THYROTROPHIN (TSH) RECEPTOR, USES THEREOF AND ANTIBODIES THERETO - The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto. | 2009-08-13 |
20090202439 | Methods for treatment of angiogenesis - The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration to a subject one or more compounds that alter the activity of VEGF pathway members, including LacCer synthase (GalT-V/VI), PECAM1, VEGFR, VEGF or related pathway members to treat a subject suffering from or susceptible to a condition caused or contributed to by VEGF. The present invention also relates to methods for detecting and analyzing compounds with therapeutic capacity to treat such condition. | 2009-08-13 |
20090202440 | MODEL ANIMAL OF DENDRITIC CELL IMMUNORECEPTOR GENE KNOCKOUT DISEASE - It is intended to disclose the function of dendritic cell immunoreceptor (DCIR) and clarify its role in the onset of autoimmune arthritis. It is also intended to provide a method of screening a substance which is useful in treating/preventing an autoimmune disease or osteoporosis. A nonhuman disease model animal characterized by having a partial or entire deficiency of a gene encoding the DCIR protein on the chromosome; a method of screening a substance which is useful in treating/preventing a DCIR-related disease, for example, an autoimmune disease such as arthropathy by using the nonhuman disease model animal as described above; and a remedy/preventive therefor. | 2009-08-13 |
20090202441 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin. | 2009-08-13 |
20090202442 | Enerceutical activation of the alternative cellular energy (ACE) pathway in therapy of diseases - Alternative cellular energy pigments (ACE-pigments) provide a source of cellular energy other than that provided through the oxidative metabolism of foods, or in the case of plants and certain bacteria, through the process of photosynthesis. In some patients, ACE pigments exist in a form that can be further energized or activated using ultraviolet (UV) light, especially if the reaction is initially triggered by the presence of suitable dyes, such as neutral red. A method is described to further enhance the activation of the ACE pathway in humans and animals deprived of ACE. The method comprises using natural or man-made sources of ACE products (enerceuticals), with or without the inclusion of a suitable dye, such as neutral red; and applying the material(s) to the skin, either directly or separated by an impermeable barrier; and illuminating the enerceutical with a UV light source. The process of activating the ACE pathway is evidenced by UV inducible fluorescence seen within areas of the patients' skin and/or mucus membranes. This fluorescence fades as the ACE pathway becomes fully activated. Activating the ACE pathway can have therapeutic benefits in various infectious and non-infectious diseases. Cited examples include autism, Morgellons disease, herpes virus infections and cellulite. | 2009-08-13 |
20090202443 | METHODS OF IMPROVING SKIN QUALITY - Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs. | 2009-08-13 |
20090202444 | Treatment and prevention of systemic Xylella fastidiosa infections of plants using antimicrobial metal compositions - An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants by | 2009-08-13 |
20090202445 | Composition of a liquid dietary supplement to treat symptoms of autism spectrum disorders in children. - The object of the present invention is to provide an all-natural dietary supplement formulation that may be beneficial to the management of behavioral and neurological symptoms associated with autism spectrum disorders; symptoms that may not be effectively improved by conventional drug treatment and behavioral therapy alone. | 2009-08-13 |
20090202446 | MICROEMULSION COMPOSITION FOR AIR FRESHENER - The present invention relates to air freshener devices of water-based liquid compositions, preferably clear liquids, that provide an improved diffusion of the composition and allow the use of fragrance materials with a wide range of characteristics, namely a wide range of clogP values. The compositions are clear microemulsions particularly adapted for use in automatic air fresheners and comprise at least 40% w/w of an aqueous phase, preferably water, an active oil in an amount of between 0.01 and 5% w/w, an oil-solubilizing system which is formed of a surfactant mixture of ionic and non-ionic surfactants, a solubilizing-aid ingredient in an amount of up to 5% w/w, and a propellant system in an amount of up to 40% w/w, wherein the perfume oil to total surfactant mixture is present at a weight ratio of between 0.2 and 4.5. | 2009-08-13 |
20090202447 | INHALANT AEROSOL FORMULATIONS CONTAINING ETHANOL - The invention relates to inhalant, propellant-free aerosol formulations containing ethanol, said formulations having defined particle size distribution sizes. | 2009-08-13 |
20090202448 | Metal lactate powder and method for preparation - The present invention relates to a method for the preparation of a new metal lactate powdery product and to the resulting product itself with new properties. The metal lactate powder of the present invention is made via spray-drying and has a higher flowability, is less sticky and dusty, has an improved dissolution rate and is very suited for tabletting purposes. The invention is also directed to product applications in which said spray-dried metal lactate product may be applied, wherein the metal is selected from zinc and magnesium. | 2009-08-13 |
20090202449 | USE OF OSTEOPONTIN IN DENTAL FORMULATIONS - Use of osteopontin for reducing plaque bacterial growth on tooth enamel and dental formulations containing osteopontin. | 2009-08-13 |
20090202450 | ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF - This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an anionic surfactant, and to methods of using and of making such compositions. | 2009-08-13 |
20090202451 | ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF - This invention relates to oral care compositions comprising a basic amino acid or salt thereof, and a small particle fraction: and to methods of using and of making these compositions. | 2009-08-13 |
20090202454 | ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF - This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions. | 2009-08-13 |
20090202455 | ORAL CARE PRODUCT AND METHODS OF USE AND MANUFACTURE THEREOF - This invention relates to oral care compositions comprising an effective amount of a salt of a basic amino acid the salt having a pH in an unbuffered solution of less than about 7.5; an effective amount of a soluble fluoride salt; and a particulate material which has a pH in an unbuffered solution of less than about 7.5; and to methods of using and of making such compositions. | 2009-08-13 |
20090202456 | NOVEL SALTS AND THEIR USES - The invention relates to novel arginine salts, compositions comprising them, and their uses. | 2009-08-13 |
20090202457 | METHOD FOR EXFOLIATING SKIN - The present invention relates to an exfoliating composition. The composition comprises a mixture. The mixture comprises phenolsulfonic acid, guaiacolsulfonic acid, and optionally sulfosalicylic acid and citric acid. | 2009-08-13 |
20090202458 | si-RNA-Mediated Gene Silencing Technology To Inhibit Tyrosinase And Reduce Pigmentation - The present invention describes compositions and methods for treating, preventing and improving hyperpigmentation, or other unwanted pigmentation of the skin, or other unwanted skin condition, such as age spots, aged skin, skin discoloration, etc., wherein the compositions include siRNA-gene silencing oligomers specific for tyrosinase. The compositions are used to treat a broad variety of pigmentation conditions, and are preferably applied to the skin, or are delivered by directed means to a site in need thereof. | 2009-08-13 |
20090202459 | PHOTOPROTECTIVE COMPOSITIONS WITH GLYCOL AND STYRENE/ACRYLATE COPOLYMER - A photoprotective composition includes one or more photoactive agents (such as a UV filter compound), one or more optimizing agents, and a copolymer booster. Such a composition provides an unexpected synergistic combination of the one or more optimizing agents and the copolymer booster for increasing at least one of SPF, UVA/UVB ratio, critical wavelength, photostability of UVA absorber and PFA, and any combinations thereof, of the composition. | 2009-08-13 |
20090202460 | Composition of a Water-Soluble Sunscreen Preparation for Acne Rosacea - The object of the invention is to provide a topical preparation for (acne) rosacea and other sensitive skin types that protects the face from harmful UV rays without the use of chemical sunscreen ingredients. It has long been found that chemical sunscreen ingredients (most popular are oxybenzone and avobenzone) can cause an increase of rosacea symptoms (flushing, erythema, papules) (Nedorost (2003) and Landers et al., 2003). Furthermore, typical waterproof sunscreen preparations also contain various forms of silicones that are used to increase the hydrophobicity of the sunscreen. These waterproof sunscreen preparations impair the release of heat from the skin. The combination of this “trapped heat” and a sensitivity to chemical sunscreen ingredients, is harmful to rosacea skin. Therefore, a sunscreen preparation that is water-soluble and uses alternative UV absorbing and UV scattering ingredients would be very useful in protecting rosacea skin from harmful UV rays. | 2009-08-13 |
20090202461 | Anhydrous cosmetic composition comprising a crosslinked polyrotaxane and an oil - The invention relates to an anhydrous cosmetic composition intended to be applied to keratinous substances, in particular the skin, the lips or the eyelashes. This composition comprises at least one crosslinked polyrotaxane polymer and at least one oil. This composition makes it possible in particular to form, on keratinous substances, a deposited layer which increases in volume by addition of water or by the action of saliva or sweat. This composition is in particular a mascara, a lipstick or a foundation formulation. | 2009-08-13 |
20090202462 | SOLID COSMETIC COMPOSTION COMPRISING A POLYESTER - The present application relates to a cosmetic composition in cast form, in a pot or as a stick, comprising at least one polyester that can be obtained by reaction:
| 2009-08-13 |
20090202463 | ANTIMICROBIAL COMPOSITIONS, PRODUCTS AND METHODS EMPLOYING SAME - Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syncytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain. Further, products incorporating the antimicrobial compositions of the present invention and methods of using the antimicrobial compositions and products are disclosed herein. | 2009-08-13 |
20090202464 | Fragrance Compounds - A method of providing a fragrant odour to an application, comprising the addition thereto of at least one compound of the formula (I) wherein X and Y are independently selected from the group consisting of —CR | 2009-08-13 |
20090202465 | Neutralised cationic polymer, composition containing said polymer and a cosmetic treatment method - The invention relates to an ethylene cationic polymer comprising at least one primary, secondary or tertiary protonable amine function which is at least partially neutralised by a polymer organic acid neutralising agent which contains at least one carboxylic, sulphonic and/or phosphonic acid function. Said invention also relates to a cosmetic or pharmaceutical composition comprising said neutralised polymer in a physiologically acceptable medium, in particular, cosmetically or pharmaceutically acceptable medium. A method for cosmetically treating keratinic materials, such as a body of face skin, nails, hairs, eyebrows and/or eyelashes, consisting in applying the inventive cosmetic composition to said keratinic materials is also disclosed. | 2009-08-13 |
20090202466 | Oligomeric Amidoamides or Amidoquats for Fabric or Hair Treatment Compositions - Provided are oligomeric amidoamines, an oligomeric amidoamine salt of the oligomeric amidoamine, and/or an oligomeric amidoquat of the oligomeric amidoamine. These materials can be used as fabric softeners in fabric softener compositions or as a hair treatment in hair treatment compositions. | 2009-08-13 |
20090202467 | SCLEROTHERAPY FOR VARICOSE VEINS - This invention is directed to pharmaceutical compositions and methods of treating varicose veins, including telangiectasias and reticular veins, and related symptoms and diseases. Embodiments comprise injection into a varicose vein of an amphiphilic block copolymer which has properties of conversion from liquid to gel state, surfactant properties, or combinations thereof. Other embodiments consist of the combination of an amphiphilic block copolymer with a co-solvent, also allowing the injected combination to form a gel within the vein. In other embodiments, an amphiphilic block copolymer is combined with a co-solvent, a sclerosant, a vasoconstrictor, water, or combinations thereof. Other embodiments of the invention include a combination of a sclerosant such as sodium tetradecyl sulfate or polidocanol with a vasoconstrictor, preferably a long-acting vasoconstrictor such as oxymetazoline. Other embodiments are directed to compositions and methods of treating venous and arteriovenous malformations and cancer. | 2009-08-13 |
20090202468 | Attractant compounds for yellow jacket wasps - The use of individual chemical compounds as attractants in traps for yellow jacket wasps | 2009-08-13 |
20090202469 | Detection of inflammatory disease and composition for preventing or treatment of inflammatory disease - A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient. | 2009-08-13 |
20090202470 | Phosphonate Analogs of Hiv Inhibitor Compounds - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2009-08-13 |
20090202471 | Molecules with effects on cellular development and function - This invention relates to methods to stabilize and/or improve the function of parenchymal cells. Also provided are systems of co-cultures of hepatocyte-stabilizing non-parenchymal cells used in bioreactor microenvironments to identify hepatic stabilizing factors by gene-expression profiling. | 2009-08-13 |
20090202472 | MOLECULES AND CHIMERIC MOLECULES THEREOF - The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-2 protein family such as IL-2, IL-2Ra, IL-2Rb, IL-2Rg or chimeric molecules thereof, such as IL-2-Fc, IL-2Ra-Fc, IL-2Rb-Fc and IL2Rg-Fc, comprising at least a portion of the protein molecule; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications. | 2009-08-13 |
20090202473 | COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART - The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof. | 2009-08-13 |
20090202474 | EXPRESSION OF ORPHAN GPR64 IN INFLAMMATORY DISEASES - Methods of screening for agents for treating inflammatory diseases are provided. The methods involve screening for agents that modulate the activity or expression of GPR64, which has been discovered herein to play a role in inflammatory diseases. Methods for treating an inflammatory disease, as well as methods of modulating the activity or expression of GPR64, methods of screening for an inflammatory disease in a subject, pharmaceutical compositions, a nucleic acid variant, and antibodies are also provided. | 2009-08-13 |
20090202475 | Compositions and methods for treatment of microbial disorders - The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions. | 2009-08-13 |
20090202476 | CRYSTALLINE FORMS OF N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-IS- OQUINOLINYL)OXY)-N-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOYL)-2-VINYLCYCL- OPROPYL)-L-PROLINAMIDE - The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms. | 2009-08-13 |
20090202477 | METHODS OF TREATING INFECTIONS USING IL-21 - Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known antimicrobial or antiviral therapeutics. | 2009-08-13 |
20090202478 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2009-08-13 |
20090202479 | Method for modulating immune responses using stem cells and cytokines - The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease (GvHD). | 2009-08-13 |
20090202480 | MACROCYCLIC SERINE PROTEASE INHIBITORS - Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2009-08-13 |
20090202481 | Composition for Sustained Release Delivery of Proteins or Peptides - The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a protein or peptide in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic non-polymeric material; (c) a protein or peptide covalently conjugated with one or more formulation performance-enhancing compounds. The present invention also provides a method of manufacturing and use of the composition thereof. | 2009-08-13 |
20090202482 | Prevention and Treatment of HCV Infection Employing Antibodies Directed Against Conformational and Linear Epitopes - Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or treat HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper treatment regimen. Pharmaceutical compositions for prevention and treatment of HCV, comprising one or more the monoclonal antibodies, are provided. | 2009-08-13 |
20090202483 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2009-08-13 |
20090202484 | MODULATORS OF TOLL-LIKE RECEPTOR 7 - The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent. | 2009-08-13 |
20090202485 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2009-08-13 |
20090202486 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS - The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: | 2009-08-13 |
20090202487 | Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology - The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In a most preferred embodiment the complex comprises an anti-CD20 IgG antibody conjugated to four IFN-α2b moieties, although other antibodies and cytokines have been used to form effect DNL complexes. | 2009-08-13 |
20090202488 | Use Of The Foamy Virus Bet Protein For Inactivating APOBEC - Described is the foamy virus Bet-mediated inactivation of the mutagenic, genome-modifying and vector-inactivating cellular enzyme ABOBEC. Such inactivation is useful for the treatment or prevention of various diseases, e.g., cancer, or for enhancing the production and genetic stability of gene therapy vectors, preferably retroviral vectors. | 2009-08-13 |
20090202489 | ADENOVIRUSES MUTATED IN THE VA GENES FOR CANCER TREATMENT - This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs. | 2009-08-13 |
20090202490 | MUTANT ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF - The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof. | 2009-08-13 |
20090202491 | Method for modulating, regulating and/or stabilizing angiogenesis - A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in need thereof, in which the PDGF-D level or activity or both in the mammal are modulated or increased. In preferred embodiments, an active PDGF-D polypeptide, or a polynucleotide encoding an active PDGF-D is administered to the mammal, preferably at a location where angiogenesis modulation or stabilization is desired. The PDGF-D is advantageously co-administered with an angiogenic growth factor, such as a member of the VEGF family of growth factors, in particular VEGF-E. The claimed method inhibits leakage of blood vessels and is useful, inter alia, for treatment of edemas. | 2009-08-13 |
20090202492 | ADENOVIRUS VACCINE UTILIZING IKK AS ADJUVANT - The invention provides an adenovirus that expresses a constitutively activated form of human NF-κB activating kinase (IKK). Co-administration of the adenovirus expressing the constitutively activated form of IKK (Ad-IKKβ) and an antigen confers an enhanced immune response against the antigen relative to co-administration of the antigen and adenovirus that do not express IKK. Optionally, the adenovirus comprises one or more heterologous nucleic acid sequences that may encode, for example, a biologically active product such as the antigen of an infectious agent (e.g., bacterial, fungal, etc.) or a tumor antigen. Accordingly, the adenovirus is useful for inducing desired immune responses such as those against infectious agents and cancer cells. | 2009-08-13 |
20090202493 | MIR-150 FOR THE TREATMENT OF BLOOD DISORDERS - The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively. | 2009-08-13 |
20090202494 | Combined use of glp-1 agonists and gastrin for regulating blood glucose levels - The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes. | 2009-08-13 |
20090202495 | Hyaluronic Acid Derivative and Neural Stem Cells for SCI and PNT Regeneration - A biomaterial for the treatment of spinal cord or of peripheral nerve injury injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from βFGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof. | 2009-08-13 |
20090202496 | METHOD FOR REGENERATING AN IMMUNE SYSTEM - An isolated and purified cell line of hematopoeitic stem cells (HSC) that are incapable of expressing the CCR5 receptor on the cell surface (“the CCR5Δ32 cells” are used to regenerate the immune system in a subject in need thereof and especially to treat a subject infected with human immunodeficiency virus (HIV). The method is carried out by transplanting CCR5Δ32 into the recipient subject. Because mature immune cells derived from CCR5Δ32 cells cannot express functional CCR5 receptors, they will be resistant to infection by HIV and other pathogens that use the CCR5 receptor to infect cells. An embodiment of the invention includes administration of a nutritional regimen to the patient that optimizes conditions for CCR5Δ32 cell transplantation. Another embodiment of the invention includes co-transplanting mesenchymal cells along with the HSC in order to enhance the growth and development of the transplanted HSC. | 2009-08-13 |
20090202497 | USE OF GLP-1, GLP-1 DERIVATIVES OR GLP-1 FRAGMENTS FOR SKIN REGENERATION, STIMULATION OF HAIR GROWTH, OR TREATMENT OF DIABETES - The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes. | 2009-08-13 |
20090202498 | DIRECT DIFFERENTIATION OF CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS - The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as SB203580 and protein growth factors of the FGF, IGF and BMP families such as but not limited to IGF1, FGF2, BMP2, BMP4 and BMP6. and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from stem cells is also provided wherein the media contains these factors. The use of cardiomyocytes and cardiac progenitors produced by the directed differentiation in transplantation and screening for cardiac compounds is also provided. | 2009-08-13 |
20090202499 | Human Telomerase Reverse Transcriptase Peptides - Tumor antigens can be categorized as tumor type specific or common. Telomerase reverse transcriptase (TRT) is the first bona fide common tumor antigen. While several 9mer peptides of the human TRT (hTRT) have been identified for HLA-A2, the most prevalent (˜50%) HLA type in humans, little information exists on peptides for the remaining HLA types. As described herein, a multi-step approach was taken to select and characterize a panel of HLA-B79mer peptides as candidate immunogens. Specifically, several of algorithm based predictions, in vivo immunization of HLA-B7 transgenic mice, in vitro immunization of human blood lymphocytes, in vivo processing and supertype binding were employed to identify HLA-B7-restricted epitopes in hTRT. A correlation between in vivo immunogenicity and actual HLA-B7 binding avidity was found for the seven predicted peptides. Furthermore, endogenous processing was found to correlate with in vitro immunogenicity in human PBMC and HLA-B7 supertype binding. | 2009-08-13 |
20090202500 | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues - The present inventors revealed the following for the first time in the world:
| 2009-08-13 |
20090202501 | Chimeric NK receptor and methods for treating cancer - The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided. | 2009-08-13 |
20090202502 | HEPATIC STELLATE CELL SPECIFIC PROMOTER AND USES THEREOF - Methods and reagents for effecting transgene expression in Hepatic Stellate Cells (HSC) comprising a 2.2 kb fragment of the promoter region of the Glial Fibrillary Acidic Protein (GFAP) gene, said construct being up-regulated by pro-fÊbronetic cytokines such as TGF-beta 1 in a dose and time dependent manner, and uses thereof. | 2009-08-13 |
20090202503 | SEQUENCE OF NUCLEOTIDES AND PEPTIDES GSE 24.2 OF DYSKERIN, WHICH CAN INDUCE TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS AND APPLICATIONS THEREOF - This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita. | 2009-08-13 |
20090202504 | METHODS FOR THE DETECTION AND PROGNOSIS OF BREAST TUMORS - This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application. | 2009-08-13 |
20090202505 | Rescue of Photoreceptors by Intravitreal Administration of an Expression Vector Encoding a Therapeutic Protein - The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells. | 2009-08-13 |
20090202506 | EX-VIVO PRIMING FOR GENERATING CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR NON-TUMOR ANTIGENS TO TREAT AUTOIMMUNE AND ALLERGIC DISEASE - Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo. | 2009-08-13 |
20090202507 | Intelligent Nanomedicine Integrating Diagnosis And Therapy - A method of controlling the activity of a biologically active compound. The method concerns an oligonucleotide-based compound, comprising a hairpin-forming oligonucleotide, an effector moiety physically associated with the oligonucleotide, where the effector moiety possesses a biological activity, and a regulating moiety physically associated with the oligonucleotide, where the regulating moiety controls the biological activity of the effector moiety by interacting with the effector moiety. The oligonucleotide can assume a hairpin configuration, where the effector and regulating moieties interact, or an open configuration, where the effector and regulating moieties fail to interact. Depending on the nature of the effector and regulating moieties, either configuration can result in the expression of the biological activity of the effector moiety. | 2009-08-13 |
20090202508 | NEGATIVE REGULATION OF HYPOXIA INDUCIBLE FACTOR 1 BY OS-9 - The present invention discloses that OS-9 interacts with both HIF-1α and HIF-1α prolyl hydroxylases. Overexpression of OS-9 promotes the hydroxylation of HIF-1α, HIF-1α binding to VHL, proteasomal degradation of HIF-1α, and loss of HIF-1-mediated transcription. OS-9 loss-of-function increases HIF-1α protein levels and HIF-1-mediated transcription under non-hypoxic conditions. These data indicate that OS-9 is an essential component of a multiprotein complex that regulates HIF-1α protein levels in an O | 2009-08-13 |
20090202509 | METHODS AND AGENTS FOR REDUCING OXIDATIVE STRESS - The present invention relates to novel methods for enhancing endogenous protection mechanisms against oxidative stress, and agents for use in such methods. In particular, the present invention provides a pharmaceutical composition which provides an oxidative signal upon administration to a subject, the signal triggering a therapeutic or prophylactic effect by priming the subject's body to combat the effects of oxidative stress. | 2009-08-13 |
20090202510 | ALTERED SUMOYLATION OF LAMIN A PROTEIN ASSOCIATED WITH DILATED CARDIOMYOPATHY - This invention relates to methods of diagnosing dilated cardiomyopathy using analysis of the lamin A protein and sumylation of same, as well as methods for treating dilated cardiomyopathy, comprising enhancing the sumoylation of the lamin A protein in a subject in need thereof. | 2009-08-13 |
20090202511 | Targeted protein replacement for the treatment of lysosomal storage disorders - The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use 10 of the compositions and methods for enzyme replacement therapy of lysosomal storage diseases. Nucleic acids, recombinant cells and kits useful for making and using the compositions of the invention are also provided. | 2009-08-13 |
20090202512 | PROTEINS FOR USE IN HUMAN AND ANIMAL STAPHYLOCOCCUS INFECTIONS - The present invention relates to a polypeptide termed ply_pitti26 comprising the sequence as depicted in SEQ ID NO: | 2009-08-13 |
20090202513 | RIBONUCLEASE AND THIAZOLIDINEDIONE COMPOUNDS AND THEIR USE IN METHODS TO TREAT CANCER - The present invention relates to methods and kits for the treatment of cancer. A novel drug combination comprising a ribonuclease compound and a thiazolidinedione compound has been identified as producing a synergistic cytotoxicity effect in cancer cells. Methods and kits pertaining to the co-administration of these compounds are discussed herein. | 2009-08-13 |
20090202514 | AGENTS FOR IMPROVING CHRONIC OBSTRUCTIVE PULMONARY DISEASES - The present invention relates to agents for suppressing pulmonary emphysematous lesions and agents for suppressing emphysematous lesions which are suitable for treating and/or preventing COPD, which comprise as an active ingredient a substance having an activity of promoting CSPG degradation, inhibiting CSPG synthesis, or inhibiting CSPG sulfation (examples of such agents are: chondroitinase ABC, C6ST antisense agents, and GalNAc antisense agents); agents for treating and/or preventing COPD; methods for suppressing emphysematous lesions; and methods for treating and/or preventing COPD. | 2009-08-13 |
20090202515 | AGENTS FOR SUPPRESSING NEURAL FIBROTIC DEGENERATION - The present invention examined the accumulation of chondroitin sulfate proteoglycans (CSPGs). The present invention relates to neurodegeneration-suppressing agents that are suitable for gene therapy or prevention of neural fibrotic degenerative diseases which induce neural cell death due to an accumulation of abnormal proteins, where the therapies are based on siRNAs against N-acetylgalactosamine-4-O-sulfotransferases (N-acetylgalactosamine-4-O-sulfotransferase-1, N-acetylgalactosamine-4-O-sulfotransferase-2, and N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase (GalNAc4ST-1, GalNAc4ST-2, and GALNAC4S-6ST, respectively)), which are sulfotransferases for acetylgalactosamine, a CSPG side chain, and chondroitinase ABC, an enzyme that degrades chondroitin sulfate, another CSPG side chain. | 2009-08-13 |
20090202516 | INHIBITION AND TREATMENT OF GASTROINTESTINAL BIOFILMS - Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of gastrointestinal biofilm infections, and associated systemic symptoms caused by biofilms associated microorganisms within the gastrointestinal tract. Methods of identification, preparation and use of such physiologically acceptable anti-biofilm compositions are also provided. | 2009-08-13 |
20090202517 | AGENTS FOR IMPROVING INFLAMMATORY BOWEL DISEASE - The present inventors discovered for the first time that intestinal inflammation could be efficiently suppressed by suppressing the production or accumulation of chondroitin sulfate proteoglycans. Specifically, inflammation in the large intestine can be suppressed by using siRNA to suppress the expression of versican, which is one of the chondroitin sulfate proteoglycans. Compounds used as siRNA, such as nucleic acids, can be used as effective agents for suppressing intestinal inflammation. Furthermore, the above finding also suggests that such intestinal inflammation-suppressing agents can be found by screening for compounds that suppress the production or accumulation of chondroitin sulfate proteoglycans. | 2009-08-13 |
20090202518 | Treatment of sepsis and inflammation with alpha2A Adrenergic antagonists - Provided are methods for treating a mammal undergoing sepsis, or at risk for sepsis. Also provided are methods of preventing or treating a physiological effect of sepsis in a mammal. Additionally provided are methods of inhibiting an inflammatory response in a mammal. Further provided is the use of an α | 2009-08-13 |
20090202519 | Compositions and methods for treating gram positive bacterial infection in a mammalian subject - Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin infection in the mammalian subject. Compositions and method are provided that comprise administering to the mammalian subject an effective amount of a compound that activates Scd1 gene expression or activates Scd1 gene product. | 2009-08-13 |
20090202520 | Treatment and diagnostic methods for fibrosis related disorders - Compositions and methods are provided for the treatment of fibrosis related disorders utilizing the ratio of the concentration of serum amyloid P(SAP) to C-reactive protein (CRP) in a patient. The methods may further comprise determining the R131/H131 polymorphism of FcγRIIA. Diagnostic methods are also provided. | 2009-08-13 |
20090202521 | Bifunctional Polyazamacrocyclic Chelating Agents - A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q | 2009-08-13 |
20090202522 | Use of goat serum for veterinary treatment - Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses. | 2009-08-13 |